{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:11:40Z","timestamp":1787026300424,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>The development of antiviral therapies for respiratory viruses continues to be a major unmet clinical need. One of the key challenges in antiviral drug discovery is the identification of preclinical systems that faithfully reproduce essential features of the human airway while retaining clinical relevance. Primary human airway epithelial cells cultured under air\u2013liquid interface (ALI) conditions provide a differentiated and polarized epithelial model with functional cilia, mucus production, barrier formation, and innate antiviral responses. Importantly, patterns of viral replication and host responses observed in ALI cultures often parallel findings from human infection studies and controlled viral challenge models. Beyond mechanistic studies of virus\u2013epithelium interactions, ALI platforms are increasingly applied to translational decision-making, including dose prediction, biomarker assessment, alignment of preclinical and clinical endpoints, and estimation of clinical trial design parameters. Clinical experience with antiviral agents such as an RSV polymerase inhibitor (PC786) and a narrow-spectrum kinase inhibitor (RV568) further supports the translational utility of these systems. This review summarises the biological rationale for ALI airway models and highlights their expanding role in bridging mechanistic research with early clinical development.<\/jats:p>","DOI":"10.3389\/fcimb.2026.1892573","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:20:45Z","timestamp":1783311645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A utility of air\u2013liquid interface cultured airway epithelium for the development of antiviral agents: translation beyond biology"],"prefix":"10.3389","volume":"16","author":[{"given":"Kazuhiro","family":"Ito","sequence":"first","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMoa2108903","article-title":"EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge","volume":"386","author":"Ahmad","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.antiviral.2018.06.007","article-title":"Antiviral drug screening by assessing epithelial functions and innate immune responses in human 3D airway epithelium model","volume":"156","author":"Boda","year":"2018","journal-title":"Antiviral Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1111\/bph.14221","article-title":"Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium","volume":"175","author":"Brookes","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003\/erj.42.Suppl_57.1970","article-title":"RV568, a narrow spectrum kinase inhibitor (NSKI), inhibits virus induced nasal interleukin-8 (IL8) in the human viral challenge model where healthy adult male volunteers were experimentally inoculated with live respiratory syncytial virus","volume":"42","author":"Cass","year":"2013","journal-title":"Eur. Respir. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1700188","DOI":"10.1183\/13993003.00188-2017","article-title":"RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-\u03b1 and -\u03b3 selectivity, suppresses COPD inflammation","volume":"50","author":"Charron","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e00737-17","DOI":"10.1128\/AAC.00737-17","article-title":"Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor","volume":"61","author":"Coates","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/infdis\/jiaa716","article-title":"Safety and antiviral effects of nebulized PC786 in a respiratory syncytial virus challenge study","volume":"225","author":"DeVincenzo","year":"2022","journal-title":"J. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01884-19","article-title":"A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein","volume":"64","author":"DeVincenzo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","first-page":"5027","article-title":"The Development of 3D Primary Co-Culture Models of the Human Airway","author":"Iriondo","year":"2025"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1144050","article-title":"An impact of age on respiratory syncytial virus infection in air-liquid-interface culture bronchial epithelium","volume":"10","author":"Ito","year":"2023","journal-title":"Front. Med. (Lausanne)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.prrv.2007.07.003","article-title":"Respiratory virus infections","volume":"8","author":"Kesson","year":"2007","journal-title":"Paediatr. Respir. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1046\/j.1440-1843.2003.00493.x","article-title":"The airway epithelium: Structural and functional properties in health and disease","volume":"8","author":"Knight","year":"2003","journal-title":"Respirology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1208\/s12248-021-00666-x","article-title":"Pulmonary delivery of aerosolized chloroquine and hydroxychloroquine to treat COVID-19: In vitro experimentation to human dosing predictions","volume":"24","author":"Kolli","year":"2022","journal-title":"AAPS J."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13030572","article-title":"A novel in vitro primary human alveolar model (AlveolAirTM) for H1N1 and SARS-CoV-2 infection and antiviral screening","volume":"13","author":"Lopes","year":"2025","journal-title":"Microorganisms"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02514","article-title":"A co-culture model of PBMC and stem cell derived human nasal epithelium reveals rapid activation of NK and innate T cells upon influenza A virus infection of the nasal epithelium","volume":"9","author":"Luukkainen","year":"2018","journal-title":"Front. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume":"58","author":"Mackman","year":"2015","journal-title":"J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","article-title":"Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates","volume":"585","author":"Maisonnasse","year":"2020","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.584940","article-title":"The rise and fall of chloroquine\/hydroxychloroquine as compassionate therapy of COVID-19","volume":"12","author":"Manivannan","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1093\/jac\/dky089","article-title":"Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium","volume":"73","author":"Mirabelli","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1165\/rcmb.2020-0010MA","article-title":"A microengineered airway lung chip models key features of viral-induced exacerbation of asthma","volume":"63","author":"Nawroth","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"L25","DOI":"10.1152\/ajplung.00256.2010","article-title":"The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epithelia","volume":"300","author":"Pezzulo","year":"2011","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"897\u2013919","DOI":"10.1038\/s41551-025-01491-9","article-title":"An immune-competent lung-on-a-chip for modelling the human severe influenza infection response","volume":"10","author":"Ringquist","year":"2025","journal-title":"Nat. Biomed. Eng"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2013.06.031","article-title":"Growth and characterization of different human rhinovirus C types in three-dimensional human airway epithelia reconstituted in vitro","volume":"446","author":"Tapparel","year":"2013","journal-title":"Virology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2026.106363","article-title":"Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals","volume":"248","author":"Toselli","year":"2026","journal-title":"Antiviral Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1128\/CMR.00014-10","article-title":"The airway epithelium: Soldier in the fight against respiratory viruses","volume":"24","author":"Vareille","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1021\/acs.accounts.1c00411","article-title":"Microfluidic organs-on-a-chip for modeling human infectious diseases","volume":"54","author":"Wang","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: Defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8182","DOI":"10.1038\/s41598-017-08567-w","article-title":"Development of a primary human co-culture model of inflamed airway mucosa","volume":"7","author":"Yonker","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1892573\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:20:46Z","timestamp":1783311646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1892573\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":28,"alternative-id":["10.3389\/fcimb.2026.1892573"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1892573","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1892573"}}